Global LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists Pipeline Insights Report 2017 - Research and Markets

DUBLIN--()--Research and Markets has announced the addition of the "LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists - Pipeline Insights, 2017" drug pipelines to their offering.

LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists-Pipeline Insights, 2017 provides comprehensive insights about pipeline drugs across this indication. A key objective of the report is to establish the understanding for all the pipeline drugs that fall under LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists.

This report provides information on the therapeutic development based on the LAG-3 Antagonists, TIM-3 Antagonists & OX40 Agonists dealing with all the pipeline drugs, comparative analysis at various stages covering Filed, Phase III, Phase II, Phase I, IND filed, Preclinical, Discovery and unknown stages, therapeutics assessment by monotherapy and combination products and molecule type drug information.

The report also covers the company's information involved in the therapeutic development of the products. It also has highlighted the discontinued and dormant products.

Key Topics Covered:

  1. LAG-3, TIM-3 & OX40 Overview
  2. Pipeline Therapeutics
  3. Therapeutics under Development by Companies
  4. Late Stage Products (Filed and Phase III)
  5. Comparative Analysis
  6. Mid Stage Products (Phase II)
  7. Comparative Analysis
  8. Early Stage Products (Phase I and IND)
  9. Comparative Analysis
  10. Discovery and Pre-clinical stage Products
  11. Comparative Analysis
  12. Drug Candidate Profiles
  13. LAG525: Novartis
  14. Product Description
  15. Research and Development
  16. GSK2831781
  17. Product Description
  18. Research and Development
  19. Other Development Activities
  20. Therapeutic Assessment
  21. Discontinued Products
  22. Dormant Products
  23. Companies involved in Therapeutics Development
  • Bristol-Myers Squibb
  • Immutep S.A.
  • Regeneron Pharmaceuticals
  • Sanofi
  • Prima BioMed Ltd
  • Ono Pharmaceutical Co. Ltd
  • Immutep S.A.
  • GlaxoSmithKline

For more information about this drug pipelines report visit http://www.researchandmarkets.com/research/gxk8lh/lag3

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Oncology Drugs

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Oncology Drugs